文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

伴RUNX1突变髓系肿瘤患者的临床特征及疗效分析

[Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析2014年7月至2018年4月苏州大学附属第一医院42例伴RUNX1突变AML/MDS患者,allo-HSCT组31例1年OS、DFS分别为(70.6±9.0)%、(61.0±9.4)%,化疗组11例分别为(34.4±16.7)%、(22.4±15.3)%,两组差异有统计学意义;移植年龄>45岁及染色体核型复杂异常为不良预后因素。

要点

  • 42例伴RUNX1突变髓系肿瘤中FLT3共突变频率最高(26.2%,11/42),且均见于AML患者(P=0.014)。
  • allo-HSCT组1年OS、DFS均高于化疗组,两组差异有统计学意义(χ²=4.843,P=0.036;χ²=4.320,P=0.047)。
  • 移植年龄>45岁为OS及DFS的不良预后因素,染色体核型复杂异常为OS的不良预后因素。

核心结论

  • allo-HSCT可以改善伴RUNX1突变髓系肿瘤患者预后。
  • 移植年龄>45岁、染色体核型复杂异常是影响allo-HSCT疗效的不良预后因素。

研究设计与样本

  • 回顾性分析2014年7月至2018年4月在苏州大学附属第一医院行二代测序检出RUNX1基因突变的42例髓系肿瘤患者的临床资料。
  • 42例中AML 30例、MDS 12例,allo-HSCT组31例、化疗组11例。

主要发现

  • 男27例、女15例,中位年龄43.5(16~68)岁。
  • 共突变基因频率最高为FLT3(26.2%,11/42),携带FLT3共突变者均为AML患者(P=0.014);MDS患者最常见共突变为ASXL1(25%,3/12)。
  • allo-HSCT组1年OS为(70.6±9.0)%、DFS为(61.0±9.4)%;化疗组1年OS为(34.4±16.7)%、DFS为(22.4±15.3)%;两组OS差异有统计学意义(χ²=4.843,P=0.036),DFS差异有统计学意义(χ²=4.320,P=0.047)。
  • 单因素分析:移植年龄>45岁为OS不良因素[HR=4.819(95%CI 1.145~20.283),P=0.032]及DFS不良因素[HR=5.945(95%CI 1.715~20.604),P=0.005];染色体核型复杂异常为OS不良因素[HR=5.572(95%CI 1.104~28.113),P=0.038]。

关键数值与推荐

  • allo-HSCT组1年OS(70.6±9.0)%、DFS(61.0±9.4)%;化疗组1年OS(34.4±16.7)%、DFS(22.4±15.3)%。
  • 移植年龄>45岁:OS的HR=4.819(95%CI 1.145~20.283),P=0.032;DFS的HR=5.945(95%CI 1.715~20.604),P=0.005。
  • 染色体核型复杂异常:OS的HR=5.572(95%CI 1.104~28.113),P=0.038。
  • FLT3共突变频率26.2%(11/42),均见于AML患者(P=0.014);MDS中ASXL1共突变25%(3/12)。

临床怎么用

  • 作者结论认为allo-HSCT可以改善伴RUNX1突变髓系肿瘤患者预后。
  • 作者结论认为移植年龄>45岁、染色体核型复杂异常是影响allo-HSCT疗效的不良预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the survival and prognostic factors of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for patients with myeloid neoplasms and RUNX1 mutations. Methods: From July 2014 to April 2018, the clinical data of forty-two AML/MDS patients with RUNX1 mutations in the First Affiliated Hospital of Soochow University were retrospectively analyzed. The clinical characteristic features and distribution of the mutations frequently observed with RUNX1 mutations were summarized, the prognosis of allo-HSCT for these patients was also analyzed. Results: Among 42 AML/MDS patients with RUNX1 mutations, 27 were male, 15 were female. The median age was 43.5 (16-68) years old. There are 31 patients in allo-HSCT group and 11 patients in chemotherapy group. RUNX1 mutations co-occurred with many other gene mutations, the most frequent mutations were FLT3 (26.2%, 11/42) . Interestingly, FLT3 mutations only occurred in AML patients compared with MDS patients (P=0.014) . ASXL1 (25%, 3/12) mutations were observed as the most frequent co-mutations in MDS patients. One-year overall survival (OS) , disease-free survival (DFS) of allo-HSCT and chemotherapy patients were (70.6±9.0) %, (61.0±9.4) % and (34.4±16.7) %, (22.4±15.3) %, respectively. When OS and DFS between allo-HSCT and chemotherapy patients were compared, significant differences (χ(2)=4.843, 4.320, P<0.05) were showed. In univariate analysis, transplant age >45 years was a negative effect for OS [HR=4.819 (95% CI 1.145-20.283) , P=0.032] and DFS [HR=5.945 (95% CI 1.715-20.604) , P=0.005]. Also, complex chromosome karyotype abnormality was a negative effect for OS [HR=5.572 (95%CI 1.104-28.113) , P=0.038]. Conclusion: Transplant age (>45 years) and complex chromosome karyotype abnormality were negative prognostic factors in allo-HSCT for myeloid neoplasms patients with RUNX1 mutations. 目的: 研究伴RUNX1突变髓系肿瘤的临床特征和异基因造血干细胞移植(allo-HSCT)的疗效。 方法: 回顾性分析2014年7月至2018年4月在苏州大学附属第一医院行二代测序检出RUNX1基因突变的42例髓系肿瘤患者的临床资料。 结果: 全部42例伴RUNX1突变髓系肿瘤患者中,男27例,女15例,中位年龄43.5(16~68)岁,急性髓系白血病(AML)30例,骨髓增生异常综合征(MDS)12例。共突变基因中频率最高的是FLT3(26.2%,11/42),携带FLT3共突变基因的均为AML患者(P=0.014)。而MDS患者中最常见的共突变为ASXL1(25%,3/12)。allo-HSCT组(31例)1年总生存(OS)、无病生存(DFS)率分别为(70.6±9.0)%、(61.0±9.4)%,化疗组(11例)1年OS、DFS率分别为(34.4±16.7)%、(22.4±15.3)%,两组OS、DFS率差异有统计学意义(χ(2)=4.843,P=0.036;χ(2)=4.320,P=0.047)。单因素分析提示移植年龄>45岁为影响患者OS及DFS的预后不良因素[HR=4.819(95%CI 1.145~20.283),P=0.032;HR=5.945(95%CI 1.715~20.604),P=0.005],染色体核型复杂异常为影响OS的预后不良因素[HR=5.572(95%CI 1.104~28.113),P=0.038]。 结论: allo-HSCT可以改善伴RUNX1突变髓系肿瘤患者预后,移植年龄>45岁、染色体核型复杂异常是影响allo-HSCT疗效的不良预后因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen SF, Wang TZ, Jiang SH, et al. [Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30612398. doi:10.3760/cma.j.issn.0253-2727.2018.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。